Should albuminuria be a focus of antihypertensive therapy goals?

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Hypertension Reports

• Publication date

  2009-09-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11906-009-0059-9PMID 19737452
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

  2009cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Renin-angiotensin blockade and kidney disease.

  2008cited by this paper
• Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality.

  2008cited by this paper
• Effect of a multifactorial intervention on mortality in type 2 diabetes.

  2008cited by this paper
• Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population.

  2008cited by this paper
• Extended prognostic value of urinary albumin excretion for cardiovascular events.

  2008cited by this paper
• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

  2008cited by this paper
• Risk Factors for Renal Dysfunction in Type 2 Diabetes

  2006cited by this paper
• Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study

  2005influential reference
• Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study

  2005influential reference
• Losartan and end‐organ protection—lessons from the renaal study

  2005influential reference
• Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.

  2005cited by this paper
• The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

  2005influential reference
• Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

  2004cited by this paper
• Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria

  2004cited by this paper
• Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy

  2004cited by this paper
• Progression of nephropathy in type 2 diabetic patients.

  2004cited by this paper
• Why is proteinuria an ominous biomarker of progressive kidney disease?

  2004cited by this paper
• Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.

  2004cited by this paper
• Effectiveness of a disease management programme for patients with type 2 diabetes mellitus and albuminuria in primary care - the PROSIT project (Proteinuria Screening and Intervention).

  2004cited by this paper
• Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

  2004cited by this paper
• Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

  2003influential reference
• Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy

  2003cited by this paper
• Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study.

  2002cited by this paper
• Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

  2002cited by this paper
• Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect

  2002cited by this paper
• Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

  2002cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).

  1998cited by this paper
• Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)

  1997cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• Effects of Converting-Enzyme Inhibition on Barrier Function in Diabetic Glomerulopathy

  1990cited by this paper

• Cardiorenal Risk Factors

  2010cites this paper